The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients

Shiraz University of Medical Sciences

Status: Completed

Conditions: Hyperphosphatemia

Treatments: Drug: Mg Oxide

Study type: Observational

Funder types: Other

Identifiers

NCT01854437

1391

Details and patient eligibility

About

Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.

Enrollment: 42 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

hemodialysis with duration>3 months serum P level >5.5 mg/dl serum Ca>8 mg/dl.

Exclusion criteria

Mg level >3 mg/dl

Trial design

42 participants in 2 patient groups

Mg Oxide

Description:

Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks

Treatment:

Drug: Mg Oxide

placebo

Description:

placebo 1 tab TDS